All In Biotech

Drug Trial Radar · NCT07865910

A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy for First-Line Therapy of Advanced Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,438 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,438

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 30, 2030

Study completion Dec 30, 2031

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Oct 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 days, up to 75 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy for First-Line Therapy of Advanced Non-Small Cell Lung Cancer.The first phase of this study is a Phase II trial, with Substudy A enrolling approximately 90 participants and Substudy B enrolling approximately 90 participants. Based on your disease pathology type, the investigator will determine which substudy you are enrolled in. Eligible participants will be randomly assigned to one of three treatment groups in a 1:1:1 ratio (similar to flipping a coin or drawing names from a hat), giving each participant an equal 1/3 chance of being assigned to any given group. Within each substudy, approximately one-third of participants will receive HLX37 at dose1combined with chemotherapy, one-third will receive HLX37 at dose2 combined with chemotherapy, and one-third will receive pembrolizumab at 200 mg combined with chemotherapy. All three treatment groups will have a treatment schedule of every three weeks (Q3W). The second phase of this study is a Phase III trial, with Substudy A enrolling approximately 820 participants and Substudy B enrolling approximately 618 participants. Again, based on your disease pathology type, the investigator will determine your enrollment into either substudy. Eligible participants will be randomly assigned to one of two treatment groups in a 1:1 ratio (similar to flipping a coin or drawing names from a hat), giving each participant an equal 1/2 chance of being assigned to either group. In each substudy, approximately half of the participants will receive HLX37 at dose selected combined with chemotherapy, and the other half will receive pembrolizumab at 200 mg combined with chemotherapy. Both treatment groups will follow a Q3W treatment schedule. Primary objective is to evaluate the efficacy of different doses of HLX37 in combination with chemotherapy vs. pembrolizumab in combination with chemotherapy as first-line therapy in participants with advanced non-small cell lung cancer (NSCLC). Secondary objectives includes: * To evaluate the safety of HLX37 in combination with chemotherapy vs. pembrolizumab in combination with chemotherapy as first-line therapy in participants with advanced NSCLC * To evaluate the pharmacokinetic (PK) profile of HLX37 * To evaluate the immunogenicity of HLX37 * To evaluate the relationship between PD-L1 expression in tumor tissues and efficacy

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • Investigational drug: HLX37 dose1, IV, Q3WDrug

    HLX37: HLX37 will be given at dose1 in Stage I via intravenous (IV) infusion once every 3 weeks (Day 1 \[D1\] of each cycle). HLX37 will be given in Stage II at a dose to be determined based on Stage I study results via IV infusion once every 3 weeks (D1 of each cycle).

  • PEMBROLIZUMAB (alone or when added to a regimen above)Drug

    Pembrolizumab: Pembrolizumab will be given at a flat dose of 200 mg via IV infusion once every 3 weeks (D1).

  • Carboplatin (Investigator discretion)Drug

    Carboplatin: AUC = 5 up to a dose of 750 mg, or AUC = 6 up to a dose of 900 mg, based on local treatment guidelines, IV, once every 3 weeks (D1), given over 15-60 min.

  • Paclitaxel or Nab-PaclitaxelDrug

    Paclitaxel: 175 mg/m2 or 200 mg/m2, based on local treatment guidelines, IV, once every 3 weeks (D1), given continuously over no less than 3 h. All participants should be pretreated with oral or intravenous steroids and antihistamines according to the local approved product label and/or standard practice. Other pretreatment medications should be administered per standard practice. Nab paclitaxel: 100 mg/m2, IV, on D1, D8, and D15 of each 3-week cycle, given continuously over no less than 30 min.

  • Pemetrexed (1)Drug

    Pemetrexed: 500 mg/m2, IV, on D1 of each 3-week cycle, given continuously over no less than 10 min.

  • Investigational drug: HLX37 dose2, IV, Q3WDrug

    HLX37 will be given at dose2 (treatment group 2) in Stage I via intravenous (IV) infusion once every 3 weeks (Day 1 \[D1\] of each cycle). HLX37 will be given in Stage II at a dose to be determined based on Stage I study results via IV infusion once every 3 weeks (D1 of each cycle).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by BICR (Phase2&3)Time frame: From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
  2. ORR assessed by BICR (phse2)Time frame: From date of the first dose of study drug until the date of death from any cause, assessed up to 24months
  3. OS (phase3)Time frame: From date of the first dose of study drug until the date of death from any cause, assessed up to 50 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Anhui Medical University - The Second Hospital

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Fourth Hospital of Hebei Medical University,

    Shijiazhuang, Hebei, China

  • Affiliated Tumor Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Harbin Medical University - Tumor Hospital (The Third Affiliated Hospital)

    Harbin, Heilongjiang, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Henan Cancer Hospital & Affiliated Cancer Hospital of Zhengzhou University

    Zhenzhou, Henan, China

  • Hubei Cancer Hospital

    Wuha, Hubei, China

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Cancer Hospital Affiliated to Shandong First Medical University

    Jinan, Shangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.